Blog
RSS FeedPosted by Michael Wonder on 30 May 2023
Family seek to raise money for lung cancer drug
29 May 2023 - A family has raised £12,000 to pay for a cancer drug for their mother, which was ...
Posted by Michael Wonder on 23 May 2023
Bayer’s Nubeqa combination recommended by NICE to treat metastatic prostate cancer
22 May 2023 - More than 47,000 new cases of prostate cancer are diagnosed every year in England. ...
Posted by Michael Wonder on 17 May 2023
Ciltacabtagene autoleucel for the treatment of patients with relapsed or refractory multiple myeloma
17 May 2023 - NICE is unable to make a recommendation on the use of ciltacabtagene autoleucel (Carvykti) for the treatment ...
Posted by Michael Wonder on 10 May 2023
Olaparib for previously treated BRCA mutation positive hormone-relapsed metastatic prostate cancer
10 May 2023 - NICE has published evidence-based recommendations on olaparib (Lynparza) for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate ...
Posted by Michael Wonder on 10 May 2023
Olaparib for adjuvant treatment of BRCA mutation positive HER2 negative high-risk early breast cancer after chemotherapy
10 May 2023 - NICE has published evidence-based recommendations on olaparib (Lynparza) for adjuvant treatment of BRCA mutation positive HER2 ...
Posted by Michael Wonder on 09 May 2023
Belantamab mafodotin for treating relapsed or refractory multiple myeloma after 4 or more therapies
9 May 2023 - The Department of Health and Social Care has asked NICE to produce guidance on using belantamab ...
Posted by Michael Wonder on 04 May 2023
Access to cancer medicines in the UK
1 May 2023 - On 31 January 2020, the UK formally ended it's 47 year membership of the EU. As a ...
Posted by Michael Wonder on 04 May 2023
Capmatinib for treating advanced non-small-cell lung cancer with MET exon 14 skipping
3 May 2023 - NICE is unable to make a recommendation on capmatinib (Tabrecta) for treating advanced non-small-cell lung cancer with ...
Posted by Michael Wonder on 03 May 2023
Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer
3 May 2023 - NICE has issued evidence-based recommendations on pembrolizumab (Keytruda) plus chemotherapy with or without bevacizumab for persistent, ...
Posted by Michael Wonder on 03 May 2023
Tafasitamab with lenalidomide for treating relapsed or refractory diffuse large B-cell lymphoma
3 May 2023 - NICE has issued evidence-based recommendations on tafasitamab (Minjuvi) with lenolidomide for relapsed or refractory diffuse large ...
Posted by Michael Wonder on 03 May 2023
Ripretinib for treating advanced gastro-intestinal stromal tumour after three or more treatments
3 May 2023 - NICE has issued evidence-based recommendations on ripretinib (Qinlock) for treating gastrointestinal stromal tumour in adults after ...
Posted by Michael Wonder on 27 Apr 2023
Two new personalised immunotherapy treatments for aggressive forms of blood cancer recommended for the Cancer Drugs Fund
27 April 2023 - NICE recommends two CAR-T therapies, both given as one-off infusions, to treat aggressive forms of blood ...
Posted by Michael Wonder on 17 Apr 2023
Daratumumab in combination with bortezomib and dexamethasone for the treatment of patients with previously treated multiple myeloma
17 April 2023 - NICE has published final draft guidance on the use of daratumumab in combination with bortezomib and ...
Posted by Michael Wonder on 08 Apr 2023
NICE final draft guidance recommends olaparib for early breast cancer and metastatic prostate cancer following new commercial deals
6 April 2023 - Ground breaking commercial deals for the anti-cancer medicine olaparib have paved the way for hundreds to benefit ...
Posted by Michael Wonder on 06 Apr 2023
Trastuzumab deruxtecan for the treatment of patients with HER2 positive unresectable or metastatic gastric or gastro-oesophageal junction cancer after anti-HER2 treatment
6 April 2023 - NICE is unable to make a recommendation on the use of trastuzumab deruxtecan (Enhertu) for the treatment ...